Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Eur Neuropsychopharmacol. 2015 May 21;25(10):1650–1660. doi: 10.1016/j.euroneuro.2015.05.006

Table 1.

Demographic characteristics of subjects with bipolar disease (BD) (n=10) and controls (n=10).

Gender1
 Age (years)2
 Postmortem delay (hours)2
 pH2
 Cause of death
 Treatment3
Pairs BD C BD C BD C BD C BD C BD C
1 M M 72 72 22 43 6.5 7.1 Suicide Accident Drug-free Drug-free
2 F F 44 49 19 40 6.5 6.8 Suicide Accident APS. BZD. Mirtazapine Drug-free
3 M M 58 54 10 23 7.1 6.5 Suicide Accident APS. Lamotrigine BZD
4 M M 40 43 17 11 6.8 6.5 Suicide Accident BZD Drug-free
5 M M 27 30 10 11 6.8 6.5 Suicide Accident Drug-free Cannabis
6 M M 63 60 8 4 6.8 7.1 Suicide Natural BZD Drug-free
7 M M 64 61 23 23 7.1 6.8 Suicide Accident BZD. Venlafaxine Drug-free
8 M M 57 55 22 22 6.5 6.5 Natural Natural Drug-free Drug-free
9 M M 63 67 31 19 6.5 7.1 Natural Natural Drug-free NSAID
10 F F 73 74 3 19 6.8 6.8 Suicide Accident Drug-free NSAID
Statistic 0.00; 14 48.504 36.004 47.004 N/A N/A

BD, Bipolar Disorder; C, control; M, male; F, female; APS, antipsychotics; BZD, benzodiazepines; NSAID, nonsteroidal anti-inflammatory drug.

1

Chi-square statistic and degrees of freedom are shown for categorical variables.

2

Mann Whitney U is shown for non-parametric variables.

3

Treatment indicates results of toxicology analysis performed by the National Institute of Toxicology, Madrid, Spain.

4

Not significant p value, p>0.05.